收费全文 | 2637篇 |
免费 | 172篇 |
国内免费 | 33篇 |
耳鼻咽喉 | 28篇 |
儿科学 | 46篇 |
妇产科学 | 63篇 |
基础医学 | 384篇 |
口腔科学 | 18篇 |
临床医学 | 185篇 |
内科学 | 733篇 |
皮肤病学 | 67篇 |
神经病学 | 329篇 |
特种医学 | 92篇 |
外科学 | 253篇 |
综合类 | 7篇 |
预防医学 | 129篇 |
眼科学 | 14篇 |
药学 | 218篇 |
中国医学 | 3篇 |
肿瘤学 | 273篇 |
2024年 | 7篇 |
2023年 | 31篇 |
2022年 | 80篇 |
2021年 | 131篇 |
2020年 | 90篇 |
2019年 | 84篇 |
2018年 | 117篇 |
2017年 | 72篇 |
2016年 | 110篇 |
2015年 | 104篇 |
2014年 | 152篇 |
2013年 | 169篇 |
2012年 | 216篇 |
2011年 | 227篇 |
2010年 | 129篇 |
2009年 | 124篇 |
2008年 | 174篇 |
2007年 | 185篇 |
2006年 | 177篇 |
2005年 | 112篇 |
2004年 | 115篇 |
2003年 | 87篇 |
2002年 | 76篇 |
2001年 | 12篇 |
2000年 | 5篇 |
1999年 | 9篇 |
1998年 | 5篇 |
1997年 | 9篇 |
1996年 | 1篇 |
1995年 | 4篇 |
1993年 | 1篇 |
1992年 | 2篇 |
1991年 | 4篇 |
1990年 | 3篇 |
1989年 | 3篇 |
1988年 | 1篇 |
1987年 | 4篇 |
1986年 | 3篇 |
1985年 | 2篇 |
1983年 | 2篇 |
1981年 | 2篇 |
1979年 | 1篇 |
Purpose
Sympathetic nervous system (SNS) hyperactivity is a salient characteristic of chronic heart failure (HF) and contributes to the progression of the disease. Iodine-123 meta-iodobenzylguanidine (123I-mIBG) imaging has been successfully used to assess cardiac SNS activity in HF patients and to predict prognosis. Importantly, SNS hyperactivity characterizes also physiological ageing, and there is conflicting evidence on cardiac 123I-mIBG uptake in healthy elderly subjects compared to adults. However, little data are available on the impact of ageing on cardiac sympathetic nerve activity assessed by 123I-mIBG scintigraphy, in patients with HF.Methods and results
We studied 180 HF patients (age?=?66.1?±?10.5 years [yrs]), left ventricular ejection fraction (LVEF?=?30.6?±?6.3 %) undergoing cardiac 123I-mIBG imaging. Early and late heart to mediastinum (H/M) ratios and washout rate were calculated in all patients. Demographic, clinical, and echocardiographic data were also collected. Our study population consisted of 53 patients aged >75 years (age?=?77.7?±?4.0 year), 67 patients aged 62–72 years (age?=?67.9?±?3.2 years) and 60 patients aged ≤61 year (age?=?53.9?±?5.6 years). In elderly patients, both early and late H/M ratios were significantly lower compared to younger patients (p?<?0.05). By multivariate analysis, H/M ratios (both early and late) and washout rate were significantly correlated with LVEF and age.Conclusions
Our data indicate that, in a population of HF patients, there is an independent age-related effect on cardiac SNS innervation assessed by 123I-mIBG imaging. This finding suggests that cardiac 123I-mIBG uptake in patients with HF might be affected by patient age.Background
Facio-Scapulo-Humeral Muscular Dystrophy (FSHD) is an autosomal dominant inherited disorder characterized by a variable and asymmetric involvement of facial, trunk, upper and lower extremity muscles. Although respiratory weakness is a relatively unknown feature of FSHD, it is not rare. Telemedicine has been used in a variety of health care fields, but only recently, with the advent of sophisticated technology, its interest among health professionals became evident, even in such diseases.Objective
To demonstrate the telemedicine efficacy in FSHD.Methods
Four siblings affected by a severe form of FSHD, living in a rural area far away from the referral center for neuromuscular diseases, who used a wheelchair, suffered from chronic respiratory failure and were provided with long-term non-invasive mechanical ventilation, received a 6-month period of telemedicine support. This consisted of video conferencing (respiratory physiotherapy, psychological support, neurological and pneumological assessment, nurse-coach supervision) and telemonitoring of cardiorespiratory variables (oxygen saturation, blood pressure, and heart rate).Results
We performed 540 video conference sessions per patient, including three daily contacts with short monitoring oximetry measurements, blood pressure, and heart-rate measurements, psychological support, neurological and pneumological assessment, nurse-coach supervision.Conclusions
Our findings indicate that our telemedicine system was user-friendly, efficient for the home treatment of FSHD, and allowed reducing hospital admissions. 相似文献Area covered: The authors describe the chemical features of tivozanib, its pharmacodynamic and pharmacokinetic properties, and the results obtained in human phase I–III clinical trials. Tivozanib received its first global approval in EU, Iceland, and Norway on 28 August 2017 for the first-line treatment of adult patients with advanced RCC and for adult patients who are VEGFR and mTOR inhibitor-naive following disease progression after one prior treatment with cytokines.
Expert opinion: The US Food and Drug Administration did not approve tivozanib due to the lack of a significant advantage in terms of survival compared to sorafenib. To date, the role of tivozanib in the pharmaceutical landscape of mRCC appears to be very limited. However, ongoing trials on the association between tivozanib and immunotherapy may represent a promising strategy to be assessed in future clinical trials. 相似文献
Methods: We performed a re-analysis of samples evaluated in a previously published cross-sectional study, regarding 96 non-transfusion-dependent thalassemia patients followed at the ‘UOSD Malattie Rare del Globulo Rosso’ Centre of the Cardarelli Hospital in Naples, Italy.
Results: We found that females were more anemic than males, but there was no significant difference in prevalence of common complications among genders, except for hypogonadism. Furthermore, the transitory regular transfusions regimen in women who had been pregnant does not seem to have a significant impact on overall prognosis.
Discussion: In non-transfusion-dependent thalassemia patients, the lower levels of hemoglobin found in females do not seem to indicate a higher prevalence of complications.
Conclusion: This data should be considered in studies with experimental treatments aiming to correct anemia in patients with non-transfusion-dependent thalassemia. It should probably also be taken into account in order to set up different transfusion regimens among genders in transfusion-dependent patients. 相似文献